Kyntra Bio
KYNB
30 hedge funds and large institutions have $5.62M invested in Kyntra Bio in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 28 closing their positions.
494% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $306K
6.45% less ownership
Funds ownership: 32.67% → 26.23% (-6.4%)
44% less funds holding
Funds holding: 54 → 30 (-24)
45% less capital invested
Capital invested by funds: $10.2M → $5.62M (-$4.6M)
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
86% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 28
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$172K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$109K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.24K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.78K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$437K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$411K |
| 3 |
Two Sigma Advisers
New York
|
-$210K |
| 4 |
Millennium Management
New York
|
-$137K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$125K |
KYNB Hedge Fund Activity: Q2 2025 in Review
30 of the 7,617 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2025, worth a combined $5.62M — down 45% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of KYNB and 4 opened new positions — a net loss of 24 holders — while 16 trimmed existing stakes and 6 added.
The largest buyer was HighTower Advisors, adding an estimated $172K. The largest seller was Primecap Management, cutting an estimated $437K.
- 30 institutional investors held Kyntra Bio (KYNB) as of Q2 2025, down from 54 in Q1 2025.
- Funds reported $5.62M of Kyntra Bio stock for Q2 2025, down 45% quarter-over-quarter.
- 4 funds opened new Kyntra Bio positions in Q2 2025 and 28 closed out, a net change of -24 holders.
- The largest Kyntra Bio buyer in Q2 2025 was HighTower Advisors, an estimated $172K added.
- The largest Kyntra Bio seller in Q2 2025 was Primecap Management, an estimated $437K sold.
Based on aggregated 13F filings for Q2 2025.